Literature DB >> 22866064

Pathological complete response of colorectal liver metastases following chemotherapy with S-1 and oxaliplatin (SOX) in combination with bevacizumab: A case report.

Tomoya Yokota1, Tsuyoshi Sano, Yasuhiro Shimizu, Daisuke Takahari, Yoshiki Senda, Masahiro Shimura, Takashi Ura, Kohei Shitara, Yuji Nimura, Yasushi Yatabe, Kei Muro.   

Abstract

Pathological complete response to systemic chemotherapy is associated with more favorable survival in patients with colorectal cancer liver metastases. We present a case of a 63-year-old man with multiple liver metastases from descending colon cancer. Following surgical resection of the primary tumor, the patient received systemic chemotherapy with S-1 and oxaliplatin in combination with bevacizumab. On achievement of a markedly favorable response to chemotherapy, surgical treatment of liver metastases was performed, and the liver tumors were successfully resected without any macroscopic residue. Histopathological analyses showed necrotic tissue in the complete absence of residual viable tumor cells. This is the first reported case of a patient with multiple liver metastases from descending colorectal cancer to achieve a pathological complete response following systemic chemotherapy with S-1 and oxaliplatin in combination with bevacizumab. This regimen is a systemic chemotherapy option to 'cure' liver metastasis from colorectal cancer.

Entities:  

Year:  2011        PMID: 22866064      PMCID: PMC3410587          DOI: 10.3892/ol.2011.256

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  25 in total

1.  Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases.

Authors:  Mehdi Karoui; Christophe Penna; Mohamed Amin-Hashem; Emmanuel Mitry; Stephane Benoist; Brigitte Franc; Philippe Rougier; Bernard Nordlinger
Journal:  Ann Surg       Date:  2006-01       Impact factor: 12.969

2.  Trends in long-term survival following liver resection for hepatic colorectal metastases.

Authors:  Michael A Choti; James V Sitzmann; Marcelo F Tiburi; Wuthi Sumetchotimetha; Ram Rangsin; Richard D Schulick; Keith D Lillemoe; Charles J Yeo; John L Cameron
Journal:  Ann Surg       Date:  2002-06       Impact factor: 12.969

3.  Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases.

Authors:  Yoji Kishi; Daria Zorzi; Carlo M Contreras; Dipen M Maru; Scott Kopetz; Dario Ribero; Manuela Motta; Nicoletta Ravarino; Mauro Risio; Steven A Curley; Eddie K Abdalla; Lorenzo Capussotti; Jean-Nicolas Vauthey
Journal:  Ann Surg Oncol       Date:  2010-06-22       Impact factor: 5.344

4.  Complete response of colorectal liver metastases after chemotherapy: does it mean cure?

Authors:  Stéphane Benoist; Antoine Brouquet; Christophe Penna; Catherine Julié; Mostafa El Hajjam; Sophie Chagnon; Emmanuel Mitry; Philippe Rougier; Bernard Nordlinger
Journal:  J Clin Oncol       Date:  2006-08-20       Impact factor: 44.544

5.  Treatment strategy for synchronous metastases of colorectal cancer: is hepatic resection after an observation interval appropriate?

Authors:  Yasuhiro Shimizu; Kenzo Yasui; Tsuyoshi Sano; Takashi Hirai; Yukihide Kanemitsu; Koji Komori; Tomoyuki Kato
Journal:  Langenbecks Arch Surg       Date:  2007-02-09       Impact factor: 3.445

6.  Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.

Authors:  Thomas Aloia; Mylène Sebagh; Marylène Plasse; Vincent Karam; Francis Lévi; Sylvie Giacchetti; Daniel Azoulay; Henri Bismuth; Denis Castaing; René Adam
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

7.  Validity of observation interval for synchronous hepatic metastases of colorectal cancer: changes in hepatic and extrahepatic metastatic foci.

Authors:  Yasuhiro Shimizu; Kenzo Yasui; Tsuyoshi Sano; Takashi Hirai; Yukihide Kanemitsu; Koji Komori; Tomoyuki Kato
Journal:  Langenbecks Arch Surg       Date:  2008-01-04       Impact factor: 3.445

8.  Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.

Authors:  Dan G Blazer; Yoji Kishi; Dipen M Maru; Scott Kopetz; Yun Shin Chun; Michael J Overman; David Fogelman; Cathy Eng; David Z Chang; Huamin Wang; Daria Zorzi; Dario Ribero; Lee M Ellis; Katrina Y Glover; Robert A Wolff; Steven A Curley; Eddie K Abdalla; Jean-Nicolas Vauthey
Journal:  J Clin Oncol       Date:  2008-10-20       Impact factor: 44.544

9.  Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma.

Authors:  Kuniaki Shirao; Atsushi Ohtsu; Hideho Takada; Yasushi Mitachi; Kosei Hirakawa; Noboru Horikoshi; Takeshi Okamura; Koichi Hirata; Soh Saitoh; Hiroharu Isomoto; Atsushi Satoh
Journal:  Cancer       Date:  2004-06-01       Impact factor: 6.860

10.  Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group.

Authors:  A Ohtsu; H Baba; Y Sakata; Y Mitachi; N Horikoshi; K Sugimachi; T Taguchi
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.